Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2022

View Archived Issues

CHIN-117 reduces inflammation in murine model of colitis

Researchers highlight use of NUAK2 inhibitor HTH-02-006 for treating prostate cancer

Eternity Bioscience patents new Raf kinase inhibitors

Athira Pharma discloses new HGFR modulators

Engineered CAR NK cells can be an effective therapy against SARS-CoV-2 infection

Lengo Therapeutics presents new EGFR and HER2 inhibitors

New NFE2L2 activators identified by Sitryx Therapeutics

Arena Pharmaceuticals synthesizes new 5-HT2A receptor antagonists

SA-FasL microgels induce immune acceptance of islet transplantation

Chemokine-targeting B7-H3.CAR-T cells show enhanced activity against NSCLC brain tumor lesions

Aging mice brains have slower protein turnover, linking aging to neurodegenerative disease

FDA awards orphan drug designation to TTI-101 for IPF

NHLBI grant supports IND-enabling studies of NMX-1 for triple-negative breast cancer

IMT-504 ameliorates neuropathic pain by modulating neuroimmune milieu

VeriSIM Life partners with Total Brain to support neurological drug development

Discovery of novel microtubule targeting agent for the treatment of cancer

Forma Therapeutics introduces USP1 inhibitor FT-3171

New myasthenia gravis rat model developed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...